Literature DB >> 1916888

Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies.

P A Broliden1, B Mäkitalo, L Akerblom, J Rosen, K Broliden, G Utter, M Jondal, E Norrby, B Wahren.   

Abstract

The importance of the dependence on single amino acids in the V3 region of HIV-1 gp120 was evaluated for virus neutralization and antibody-dependent cellular cytotoxicity (ADCC). Synthetic overlapping 15-mer peptides and a set of omission peptides covering amino acids 301-317 were used. Sera from 29 HIV-1-infected individuals at different stages of disease were tested for neutralization, ADCC and specific IgG reactivity. Six HIV-1 neutralizing monoclonal antibodies (mAb) acted as controls. All mAb reacted with a region (amino acids 304-318) of gp120, previously shown to induce neutralizing antibodies. The amino acids essential for reactivity were identified to be within the sequence GPGR (amino acids 312-315). The importance of this region for occurrence of neutralizing antibodies in infected humans was investigated using the same set of peptides. Out of 29 individuals, 21 were found to have neutralizing antibodies in titres between 100 and 1000. Among the neutralization-positive sera, 17/21 (81%) reacted with amino acids 304-318, compared with only one of eight sera (13%) negative in neutralization. When any of the four amino acids G, P, G or R were deleted, the seroreactivity decreased considerably. The conserved sequence GPGR was therefore considered to be the most important for neutralization in this region in human sera as well. Thus, the conserved sequence GPGR in the V3 region of gp120 is critical for virus neutralization by human HIV-1-specific antibodies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1916888      PMCID: PMC1384562     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  43 in total

1.  Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein.

Authors:  L A Lasky; J E Groopman; C W Fennie; P M Benz; D J Capon; D J Dowbenko; G R Nakamura; W M Nunes; M E Renz; P W Berman
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

2.  Superinfection of a chimpanzee with a second strain of human immunodeficiency virus.

Authors:  P N Fultz; A Srinivasan; C R Greene; D Butler; R B Swenson; H M McClure
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity.

Authors:  R H Meloen; R M Liskamp; J Goudsmit
Journal:  J Gen Virol       Date:  1989-06       Impact factor: 3.891

4.  Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide.

Authors:  A G Dalgleish; T C Chanh; R C Kennedy; P Kanda; P R Clapham; R A Weiss
Journal:  Virology       Date:  1988-07       Impact factor: 3.616

5.  Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection.

Authors:  B Wahren; L Morfeldt-Månsson; G Biberfeld; L Moberg; A Sönnerborg; P Ljungman; A Werner; R Kurth; R Gallo; D Bolognesi
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

7.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

8.  Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.

Authors:  H K Lyerly; D L Reed; T J Matthews; A J Langlois; P A Ahearne; S R Petteway; K J Weinhold
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

9.  Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.

Authors:  D D Ho; J C Kaplan; I E Rackauskas; M E Gurney
Journal:  Science       Date:  1988-02-26       Impact factor: 47.728

10.  Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis.

Authors:  J N Weber; P R Clapham; R A Weiss; D Parker; C Roberts; J Duncan; I Weller; C Carne; R S Tedder; A J Pinching
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

View more
  14 in total

1.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

3.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.

Authors:  J P Moore; M Thali; B A Jameson; F Vignaux; G K Lewis; S W Poon; M Charles; M S Fung; B Sun; P J Durda
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

4.  Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.

Authors:  A McKnight; C Shotton; J Cordell; I Jones; G Simmons; P R Clapham
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Peptides isolated from random peptide libraries on phage elicit a neutralizing anti-HIV-1 response: analysis of immunological mimicry.

Authors:  K Lundin; A Samuelsson; M Jansson; J Hinkula; B Wahren; H Wigzell; M A Persson
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

6.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

7.  A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro.

Authors:  M Levi; M Sällberg; U Rudén; D Herlyn; H Maruyama; H Wigzell; J Marks; B Wahren
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  P A Broliden; A von Gegerfelt; P Clapham; J Rosen; E M Fenyö; B Wahren; K Broliden
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

10.  Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope.

Authors:  M Ohlin; J Hinkula; P A Broliden; R Grunow; C A Borrebaeck; B Wahren
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.